Introduction {#s1}
============

Bilirubin is produced mainly by the turnover of red blood cells and then transported to the liver *via* the solute carrier organic anion transporter family member 1B (SLCO1B) ([@B25]). In the liver, Uridine diphospho-glucuronosyl transferase 1A1 (UGT1A1) catalyzes the binding of unconjugated bilirubin and glucuronic acid molecules into hydrophilic form that is excreted into bile ([@B4]).

Several studies have demonstrated the potential contribution of genetic factors to human serum unconjugated bilirubin levels ([@B14]; [@B6]). Among the genes involved in bilirubin metabolism, *UGT1A1* gene is considered to be a major factor controlling serum bilirubin levels ([@B14]). Polymorphisms in the promoter and coding region of the *UGT1A1* gene often underline Gilbert Syndrome (GS), a mild unconjugated hyperbilirubinemia condition ([@B3]; [@B28]). In Caucasian and African populations, the most common polymorphism of *UGT1A1* is an additional TA repeat in the TATA box region of the promoter, i.e., A(TA)~7~TAA (35.7--41.5%) ([@B1]; [@B13]; [@B9]), while the predominant variation in Asians is a missense mutation, c.211G \> A (p.G71R) (11--33.2%) ([@B2]; [@B3]; [@B30]). An exome-wide association study demonstrated that *UGT1A1* intronic variations may also reduce UGT1A1 enzyme activity and cause unconjugated hyperbilirubinemia ([@B19]). Moreover, the compound heterozygous *UGT1A1* variant has also been reported in GS ([@B23]), suggesting that *UGT1A1* variant may have a cumulative effect on unconjugated hyperbilirubinemia. However, the evidence for this issue is limited.

Another liver-expressing gene, *SLCO1B*, which is closely related to the transportation of bilirubin and organic anions into hepatocytes, has also been found to play a role in bilirubin homeostasis ([@B5]). Some genome-wide association studies (GWAS) suggested that polymorphisms in *SLCO1B1* and *SLCO1B3* reached genome-wide significance associated with bilirubin levels ([@B14]; [@B21]; [@B15]; [@B6]). Further, *SLCO1B1* variations c.388G \> A (p.N130D, rs2306283) and c.521T \> C (p.V174A, rs4149056) were also found to be risk factors for neonatal unconjugated hyperbilirubinemia ([@B13]; [@B5]). But the relationship between these *SLCO1B* polymorphisms and unconjugated hyperbilirubinemia in adults is unclear. Furthermore, the genetic basis, especially the combined effects of *UGT1A1* and *SLCO1B* genes for unconjugated hyperbilirubinemia in Chinese descendants has not been fully illuminated. This study aims to determine the potential effects of liver-expressing *UGT1A1* and *SLCO1B* polymorphic variants and their combined effects on mild non-hemolytic unconjugated hyperbilirubinemia.

Patients and Methods {#s2}
====================

Study Subjects {#s2_1}
--------------

This is a retrospective case-control study. Adult patients who attended routine health checkups at the second affiliated hospital of Luohe Medical College from June to July in 2017, and with the bilirubin detection results of predominantly unconjugated hyperbilirubinemia (total bilirubin ranged from 17.1 to 85 µmol/l), were enrolled in this study. The 158 control subjects were enrolled from the same health examination people with bilirubin values of less than 17.1 µmol/l. Blood samples were taken in 10--12 h fasting state in the morning and the subjects were kept from strenuous exercise. And clinical records including the gender, age as well as biochemical test results were collected. Exclusion criteria were: (1) a history of chronic liver disease (viral hepatitis, autoimmune liver disease, or cirrhosis and so on); (2) abnormal liver functions (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 50 U/L); (3) hemolysis signs (hemoglobin \<100 g/L, positive Coomb\'s test); (4) evidence of infection or biliary obstruction or pregnancy; (5) a history of drug use within 6 months.

This Study Was Approved by the Ethics Committee of Beijing You an Hospital, Capital Medical University and a Written Informed Consent Form Was Obtained From All Participants.

Molecular Analysis {#s2_2}
------------------

Genomic DNA was extracted from whole blood using a QIAamp DNA Blood Mini Kit 51106 (QIAGEN, Germany) according to the manufacturer\'s recommended protocol. The promoter, all 5 exons, exon--intron boundaries, and a region in the distal promoter (the phenobarbital response enhancer module, PBREM) of *UGT1A1* were PCR amplified and sequenced, as reported before ([@B13]). Similarly, the four known *SLCO1B* polymorphisms (388A \> G and 521T \> C within the *SLCO1B1* gene, IVS8+2087T \> C and g.21074122C \> T within the *SLCO1B3* gene) were investigated. The PCR products were purified from agarose gel and sequenced *via* an ABI3730XL sequencer (Applied Biosystems, Foster City, CA, USA).

Selection of SNPs was done based on their association with serum bilirubin levels as well as their prevalence in Asia population ([@B12]; [@B15]; [@B32]; [@B6]; [@B3]). Finally, a total of 14 SNPs (10 of *UGT1A1* and 4 of *SLCO1B*) were selected. Analysis of linkage disequilibrium (LD) and haplotype were performed by using SNPStats website (<https://www.snpstats.net/start.htm>). Strong LD was defined as both \|D′\| and r^2^ \> 0.8.

Statistical Analysis {#s2_3}
--------------------

Continuous variables were expressed as mean and standard deviation (SD) and then statistically evaluated by using Student\'s t-test. Categorical variables were compared by using the chi-squared (χ^2^) test. Logistic regression models were performed to evaluate the effects of SNPs on hyperbilirubinemia. The odds ratios (ORs) with corresponding 95% confidence interval (CI) were estimated between the case and the control groups by using binary logistic regression models after adjusting for clinical factors (including sex, age, hemoglobin, platelet, and albumin). The relation between log-transformed total bilirubin (TB) and different genotypes was also assessed. All statistical analyses were performed by using SPSS version 23.0 (SPSS, Chicago, IL, USA). A P-value \< 0.05 was considered to be statistically significant.

Results {#s3}
=======

Clinical Characteristics {#s3_1}
------------------------

A total of 146 adults with hyperbilirubinemia were enrolled in the case group and 158 adults with bilirubin values of less than 17.1µmol/L in the control group. The clinical features of the case and control groups are shown in [**Table 1**](#T1){ref-type="table"}. The average total bilirubin of the case group and the control group were 24.93 ± 9.71 µmol/l and 11.83 ± 3.04 µmol/L, respectively. Compared with control subjects, case group had a higher level of hemoglobin (HB) (142.19 ± 14.44 g/L vs 137.24 ± 16.47 g/L, *P* = 0.006) and albumin (ALB) (44.98 ± 3.65 g/L vs 44.12 ± 2.27 g/L, *P* = 0.016), but lower platelet (PLT) values (218.53 ± 54.10×10^9^/L vs 231.38 ± 52.13 × 10^9^/L, *P* = 0.026). Besides, there were no obvious differences between the case and the control groups concerning age, gender, blood routine, and other plasma biochemical results.

###### 

Clinical characteristics of case group and control group.

  Parameter            Cases (N = 146)   Controls (N = 158)   *P*
  -------------------- ----------------- -------------------- ---------
  Gender, female (%)   66 (45.21%)       77 (48.73%)          0.538
  Age (years)          40.86 ± 12.32     40.00 ± 6.98         0.462
  WBC(×10^9^/L)        6.01 ± 1.38       6.33 ± 1.51          0.052
  HB (g/L)             142.19 ± 14.44    137.24 ± 16.47       0.006
  PLT (×10^9^/L)       218.53 ± 54.10    231.38 ± 52.13       0.026
  ALT (U/L)            20.61 ± 10.28     20.06 ± 9.22         0.624
  AST (U/L)            19.25 ± 5.05      18.56 ± 4.66         0.217
  γ-GT (U/L)           21.87 ± 19.13     20.97 ± 11.88        0.62
  ALP (U/L)            69.95 ± 24.82     66.92 ± 17.55        0.218
  TB (μmol/L)          24.93 ± 9.71      11.83 ± 3.04         \<0.001
  DB (μmol/L)          8.95 ± 4.54       4.41 ± 1.20          \<0.001
  IB (μmol/L)          15.97 ± 6.82      7.46 ± 2.00          \<0.001
  TP (g/L)             76.07 ± 6.73      75.54 ± 4.02         0.414
  ALB (g/L)            44.98 ± 3.65      44.12 ± 2.27         0.016
  GLB(g/L)             5.51 ± 3.66       6.10 ± 2.66          0.121
  FPG (mmol/L)         4.99 ± 0.80       4.86 ± 0.51          0.106
  TC (mmol/L)          4.40 ± 0.84       4.41 ± 0.71          0.896
  TG (mmol/L)          1.40 ± 0.78       1.53 ± 1.02          0.211
  HDL (mmol/L)         1.32 ± 0.29       1.27 ± 0.28          0.096
  LDL (mmol/L)         2.64 ± 0.69       2.65 ± 0.63          0.907
  BUN (mmol/L)         4.72 ± 1.03       4.85 ± 1.13          0.319
  CR (mmol/L)          67.63 ± 11.58     67.27 ± 12.39        0.803
  UA (μmol/L)          324.59 ± 92.30    321.18 ± 87.54       0.824

P-values were calculated between groups by using t-test for continuous variables and the χ^2^ test for categorical variables.

WBC, white blood cell count; HB, hemoglobin; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, glutamyltransferase; ALP, alkaline phosphatase; TB, total bilirubin; DB, direct bilirubin; IB, indirect bilirubin; TP, total protein; ALB, albumin; GLB, globulin; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BUN, blood urea nitrogen; CR, creatinine; UA, uric acid.

*UGT1A1* and *SLCO1B* Gene Polymorphisms {#s3_2}
----------------------------------------

The frequencies of *UGT1A1* variations are presented in [**Table S1**](#SM1){ref-type="supplementary-material"}. The incidence of the two most common variants (either heterozygous or homozygous variants) in the case group was significantly higher than that of the control group \[(TA)~6~\>(TA)~7~: 41.78% vs 22.78%, P \< 0.001; c.211G \> A: 50.68% vs 29.11%, P \< 0.001\]. In addition, 8.22% of cases featured homozygous (TA)~7~ variant, while no controls carried this homozygous variation. The incidence of other six *UGT1A1* variations in the case group was also significantly higher for c.-3275T \> G (65.07% vs 43.04%, *P* \< 0.001), c.-3152G \> A (43.84% vs 23.42%, *P* \< 0.001), c.686C \> A (6.85% vs 1.90%, *P* = 0.033), IVS1+2842G \> T (43.15% vs 23.42%, *P* \< 0.001), IVS1+2925T \> G (43.15% vs 23.42%, *P* \< 0.001), and c.1091C \> T (11.49% vs 1.90%, *P* = 0.001), but lower for IVS2+15T \> C (5.48% vs 13.29%, *P* = 0.021). The proportion of case subjects with c.1456T \> G variant was not statistically different from that of control subjects (3.42% vs 0.63%; *P* = 0.182). Moreover, the three variants c.686C \> A, c.1091C \> T, and c.1456T \> G presented only heterozygous forms or wild-type in cases and controls. The LD pattern across the multiple SNPs of *UGT1A1* is shown in [**Table S2**](#SM1){ref-type="supplementary-material"}. Strong pairwise LD was observed among the four SNPs within *UGT1A1* \[(TA)n repeat, c.-3152G \> A, IVS1+2842G \> T and IVS1+2925T \> G\], where each \|D′\| \> 0.8 and r^2^ \> 0.8. Moderate LD was present between (TA)n repeat polymorphism and c.-3275T \> G (\|D′\| \> 0.8 and r^2=^ 0.4320).

The frequencies of different genotypes of the *SLCO1B* gene observed among the cases and controls are also shown in [**Table S1**](#SM1){ref-type="supplementary-material"}. The four known polymorphisms (388G \> A and 521T \> C within *SLCO1B1*, IVS8+2087T \> C and g.21074122C \> T within *SLCO1B3*) were investigated in this study. However, there was only a statistical difference of the frequency of 521T \> C variation between the case and the control groups (24.66% vs 13.92%, *P* = 0.017). A low pairwise LD was found between the four polymorphisms of *SLCO1B* (r^2^ \< 0.3) ([**Table S3**](#SM1){ref-type="supplementary-material"}).

Effects of *UGT1A1* or *SLCO1B* Gene Variants on Unconjugated Hyperbilirubinemia {#s3_3}
--------------------------------------------------------------------------------

Initially, the OR with 95% CI of single suspected variant for hyperbilirubinemia was assessed by using separate binary logistic regression ([**Table 2**](#T2){ref-type="table"}). Further, the results adjusted for gender, age, hemoglobin, PLT, and albumin were also calculated by multivariate logistic regression models ([**Table 2**](#T2){ref-type="table"}). Four variants of *UGT1A1* and one variant of *SLCO1B1* revealed statistical significance. Among the variations that significantly increased the risk of hyperbilirubinemia, the first priority in descending order was c.1091C \> T (OR = 7.596, 95% CI: 1.992--28.956, *P* = 0.003). There were also strong associations between other common variations in *UGT1A1* and hyperbilirubinemia, including c.-3275T \> G (OR = 2.345, 95% CI: 1.371--4.012, *P* = 0.002), (TA)~6~\>(TA)~7~ (OR = 2.383, 95% CI: 1.351-4.203, *P* = 0.003), and c.211G \> A (OR = 2.985, 95% CI: 1.71--5.211, *P* \< 0.001). Variant IVS2+15T \> C appeared to reduce the risk of hyperbilirubinemia (OR = 0.278, 95% CI: 0.095--0.82, *P* = 0.02). Specifically, variant c.521T \> C within *SLCO1B1* was found to have a significantly increased risk of hyperbilirubinemia (OR = 2.544, 95% CI: 1.267--5.11, *P* = 0.009). The log10-transferred TB of different variants is shown in [**Figure S1**](#SM1){ref-type="supplementary-material"}. After log10-transferred, the upper limit of the normal TB level is 1.23. In summary, subjects with most homozygous or heterozygous variants of *UGT1A1* or variant c.521T \> C of *SLCO1B1* have higher bilirubin values than those with wild type. However, in the cases of variants IVS2+15T \> C or IVS7+2087T \> C, the opposite is true.

###### 

ORs and 95% CIs for unconjugated hyperbilirubinemia associated with genetic variation.

  SNP                            OR     95% CI        *P*       OR\*   95% CI\*      *P*\*
  ------------------------------ ------ ------------- --------- ------ ------------- ---------
  Variant within *UGT1A1* gene                                                       
  c.-3275T \> G                  2.47   1.55--3.92    \<0.001   2.35   1.37--4.01    0.002
  (TA)~6~\>(TA)~7~               2.43   1.48--4.00    \<0.001   2.38   1.35--4.20    0.003
  c.211G \> A                    2.50   1.56--4.01    \<0.001   2.99   1.71--5.21    \<0.001
  c.686C \> A                    3.80   1.02--14.09   0.046     2.19   0.48--10.02   0.312
  IVS2 + 15T \> C                0.38   0.16--0.88    0.025     0.28   0.09--0.82    0.02
  c.1091C \> T                   6.81   1.95--23.75   0.003     7.60   1.99--28.96   0.003
  c.1456T \> G                   5.57   0.64--48.23   0.119     4.28   0.45--40.59   0.205
  Variant within *SLCO1B* gene                                                       
  *c*.388G \> A                  1.25   0.51--3.06    0.62      1.11   0.40--3.10    0.84
  c.521T \> C                    2.02   1.13--3.64    0.02      2.54   1.27--5.11    0.009
  IVS7 + 2087T \> C              0.74   0.19--2.80    0.65      1.20   0.22--6.56    0.834
  g.21074122C \> T               0.68   0.38--1.204   0.186     0.72   0.36--1.42    0.34

\*Adjusted with gender, age, HB, PLT, ALB, WBC, FPG, and HDL. SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

To assess the impact of co-expression of *UGT1A1* or *SLCO1B* variants, the relationship between the number of genetic variants and the risk of unconjugated hyperbilirubinemia was investigated. The OR is positively correlated with the cumulative number of five variants in individuals ([**Table 3**](#T3){ref-type="table"}). Adjust ORs in adults with one, two, three, and four risk variants were 3.98 (95% CI: 1.48--10.69, *P* = 0.006), 10.92 (95% CI: 3.91--30.53, *P* \< 0.001), 18.43 (95% CI: 5.95--57.04, *P* \< 0.001) and 34.38 (95% CI: 3.05--387.32, *P* = 0.004), respectively. Besides, the greater the number of genetic variations, the higher the total bilirubin level ([**Figure 1**](#f1){ref-type="fig"}). These data indicated that different variants in *UGT1A1* or *SLCO1B* have combined effects on unconjugated hyperbilirubinemia.

###### 

Adjusted ORs and 95% CI of unconjugated hyperbilirubinemia associated with the number of genetic variation.

  Number of genetic variants[^a^](#fnT3_1){ref-type="table-fn"}   Cases (N = 146)   Controls (N = 158)   OR      95% CI         P
  --------------------------------------------------------------- ----------------- -------------------- ------- -------------- ---------
  0                                                               10                45                   1.00    --             --
  1                                                               38                68                   3.98    1.48--10.69    0.006
  2                                                               54                30                   10.92   3.91--30.53    \<0.001
  3                                                               39                13                   18.43   5.95--57.04    \<0.001
  4                                                               5                 2                    34.38   3.05--387.32   0.004

All results were adjusted with gender, age, HB, PLT, ALB, WBC, FPG, and HDL.

Variants including c.-3275T \> G, (TA)~6~\>(TA)~7~, c.211G \> A, and c.1091C \> T in UGT1A1 as well as variant c.521T \> C in SLCO1B1.

OR, odds ratio; CI, confidence interval.

![Total bilirubin values (log10-transformed) amongst different numbers of genetic variants. TB, total bilirubin. \**P* \< 0.05 \*\**P* \< 0.01.](fgene-10-01073-g001){#f1}

Combined Effects of *UGT1A1* Variants on Unconjugated Hyperbilirubinemia {#s3_4}
------------------------------------------------------------------------

To further analyze the combined effects of *UGT1A1* variations on unconjugated hyperbilirubinemia, haplotype and diplotype analyses were performed. Based on multivariate logistic regression results, four SNPs of *UGT1A1*, which increased the risk of hyperbilirubinemia, formed 5 common haplotypes with frequencies \> 1% ([**Table 4**](#T4){ref-type="table"}). Among them, haplotype 1 \[--3275T--(TA)~6~--211G--1091C\] is the most common (43.52%), representing wild type. Compared with haplotype 1, haplotypes 2 \[--3275T--(TA)~6~--211A--1091C\], 3 \[--3275G--(TA)~7~--211G--1091C\], 4 \[--3275G--(TA)~6~--211G--1091C\] and 5 \[--3275G--(TA)~6~--211G--1091A\] all increased the risk of unconjugated hyperbilirubinemia (P \< 0.05).

###### 

ORs and 95% CIs for unconjugated hyperbilirubinemia associated with *UGT1A1* haplotypes.

  Haplotype   Variant                     OR (95%CI)   *P*      OR (95%CI)\*   *P*\*                                                 
  ----------- --------- --------- --- --- ------------ -------- -------------- --------------------- --------- --------------------- ---------
  1           T         (TA)~6~   G   C   26.15%       59.49%   43.52%         1.00                  --        1.00                  --
  2           T         (TA)~6~   A   C   30.70%       15.82%   22.93%         4.51 (2.77--7.35)     \<0.001   5.72 (3.19--10.26)    \<0.001
  3           G         (TA)~7~   G   C   25.00%       11.39%   17.93%         5.29 (3.07--9.11)     \<0.001   6.24 (3.29--11.86)    \<0.001
  4           G         (TA)~6~   G   C   11.86%       12.34%   12.07%         2.07 (1.16--3.68)     0.014     2.27 (1.15--4.47)     0.019
  5           G         (TA)~6~   G   T   5.82%        0.95%    3.29%          12.48 (3.36--46.38)   \<0.001   16.64 (3.89--71.12)   \<0.001

\*Adjusted with gender, age, HB, PLT, ALB, WBC, FPG, and HDL. OR, odds ratio; CI, confidence interval.

All subjects were divided into 14 diplotypes, covering a total of 303 (99.7%) adults. All bilirubin values (log10-transformed) among *UGT1A1* diplotypes are shown in [**Figure 2A**](#f2){ref-type="fig"}. Except for 4/4, subjects with homozygous variants or compound heterozygous variants (2/2, 2/3, 2/4, 2/5, 3/3, 3/4, 3/5, 4/5) had the highest levels of total bilirubin, followed by those with heterozygous variants (1/2, 1/3, 1/4, 1/5), while wild type (1/1) the lowest. Of all *UGT1A1* diplotypes, 3/3 (homozygous variation of c.-3275T \> G and (TA)~6~\>(TA)~7~) featured the highest levels of bilirubin. The diplotypes 1/4 and 4/4 represent heterozygous or homozygous c.-3275T \> G variant, respectively, and their bilirubin levels are lower than normal. Moreover, adults carrying diplotype 3/4 (homozygous c.-3275T \> G and heterozygous (TA)~6~\>(TA)~7~) had higher bilirubin levels than those with diplotypes 1/3 (heterozygous c.-3275T \> G and (TA)~6~\>(TA)~7~)) or 1/4 (heterozygous c.-3275T \> G) (*P* \< 0.05) ([**Figure 2B**](#f2){ref-type="fig"}). Similarly, bilirubin levels in individuals with diplotype 2/4 (heterozygous c.-3275T \> G and c.211G \> A) were higher than those of adults carrying diplotypes 1/2 (heterozygous c.211G \> A) or 1/4 (*P* \< 0.001). However, there was no significant difference in bilirubin levels among adults with diplotype 1/4, 1/5 or 4/5. These data demonstrated an additive effect of variants c.-3275T \> G and (TA)~6~\>(TA)~7~ or c.211G \> A on unconjugated hyperbilirubinemia.

![Total bilirubin values (log10-transformed) amongst adults with various *UGT1A1* genotypes. a: --3275T--(TA)~6~--211G--1091C; b: --3275T--(TA)~6~--211A--1091C; c: --3275G--(TA)~7~--211G--1091C; d: --3275G--(TA)~6~--211G--1091C; e: --3275G--(TA)~6~--211G--1091A. \*: *P* \< 0.05 \*\*: *P* \< 0.01.](fgene-10-01073-g002){#f2}

Combined Effects of *UGT1A1* and *SLCO1B* Variants on Unconjugated Hyperbilirubinemia {#s3_5}
-------------------------------------------------------------------------------------

The association between the two common variations (TA)~6~/(TA)~7~ and c.211G \> A in *UGT1A1* and variation c.521T \> C in *SLCO1B* was further explored. In *UGT1A1*-normal subjects, homozygous variation c.521T \> C increased total bilirubin level and the incidence of unconjugated hyperbilirubinemia compared to wild-type or heterozygous forms ([**Table S4**](#SM1){ref-type="supplementary-material"}). When carried heterozygous variation c.211G \> A, the total bilirubin level of heterozygous c.521T \> C adults was higher than that of wild type (22.92µmol/L vs 17.21µmol/L, *P* = 0.046); as the number of variation c.521T \> C alleles increased, the incidence of unconjugated hyperbilirubinemia increased, but it was not statistically significant (*P* = 0.186). When carried homozygous variation c.211G \> A, the incidence of hyperbilirubinemia for individuals featured c.521T \> C was higher, but it did not reach statistically significant (100% vs 75%, *P* = 0.214). In addition, among the 21 adults with the homozygous c.211G \> A, all 5 subjected with the heterozygous variation c.521T \> C suffered from hyperbilirubinemia. But for (TA)~6~\>(TA)~7~, we did not observe similar results. These data indicated a cumulative effect of variants c.521T \> C and c.211G \> A on unconjugated hyperbilirubinemia.

Discussion {#s4}
==========

GS, a benign condition that occurs in 5--10% of the population ([@B28]), is characterized by mild unconjugated hyperbilirubinemia, in the absence of liver disease or hemolysis ([@B24]). Although it has long been considered a benign condition and does not require treatment, recent data suggest that affected individuals may be prone to liver damage following various drugs and xenobiotic treatments ([@B8]). Molecular defects in genes involved in the bilirubin metabolic pathway account for hyperbilirubinemia. In the present study, we evaluated the effects of *UGT1A1* and *SLCO1B* on mild unconjugated hyperbilirubinemia in adults. Our results indicated that variations of *UGT1A1* and *SLCO1B* genes had a substantial impact on unconjugated bilirubin levels in Chinese adults. Notably, variant c.521T \> C in the *SLCO1B* may be independent genetic risk factors for inherited unconjugated hyperbilirubinemia. Furthermore, the risk of unconjugated hyperbilirubinemia is positively correlated with the cumulative number of variants in adults. To our knowledge, this is the first report that showed the combined effect of *UGT1A1* and *SLCO1B* variants on mild unconjugated hyperbilirubinemia in adults.

Two common variants (TA)~6~\>(TA)~7~ and c.211G \> A of *UGT1A1* both reduce UGT1A1 enzyme activity and increase unconjugated bilirubin level ([@B22]; [@B1]; [@B17]). Our results confirmed the strong association of variants (TA)~6~\>(TA)~7~ and c.211G \> A with the incidence of unconjugated hyperbilirubinemia. Additionally, the frequencies of variants (TA)~6~\>(TA)~7~ and c.211G \> A in the case group were significantly higher than those in the control group. And subjects with these two heterozygous or homozygous variants had higher mean total serum bilirubin levels than adults carrying the wild type.

Other mutations occurring in the coding region of *UGT1A1* c.686C \> A, c.1091C \> T and c.1456T \> G can also lead to Gilbert syndrome amongst the Asian population ([@B12]; [@B31]). In this study, the frequencies of variants c.686C \> A and c.1091C \> T in the *UGT1A1* gene in cases and controls were statistically different, but only the OR of c.1091C \> T was statistically significant when adjusting the covariates. The role of variants c.686C \> A and c.1456T \> G needs to be explored through large-scale investigations. Besides, we found that variant IVS2+15T \> C appears to reduce the risk of hyperbilirubinemia, and is associated with lower bilirubin levels. However, there is no relevant evidence and further research is needed.

Earlier studies suggested the decrease in transcription caused by both (TA)~6~\>(TA)~7~ and c.-3275T \> G mutations together may be essential to the Gilbert syndrome ([@B16]). In the present study, variation c.-3275T \> G was found to be moderately linked with TA repeats. The results of multivariate logistic regression and haplotype analysis demonstrated that variant c.-3275T \> G was an independent risk factor of unconjugated hyperbilirubinemia. Interestingly, subjects carrying homozygous or heterozygous variant c.-3275T \> G (4/4 or 1/4 diplotype) featured normal mean bilirubin levels. This result is consistent with other researches, suggesting that variant c.-3275T \> G was not associated with increased bilirubin levels ([@B2]; [@B20]). In addition, diplotype analyses revealed that subjects with co-inheriting heterozygous variants c.-3275T \> G as well as (TA)~6~\>(TA)~7~ or c.211G \> A had higher bilirubin levels than those carrying any of the above heterozygous variants. These data indicate a combined effect on unconjugated hyperbilirubinemia for different variants in *UGT1A1*.

Some GS cases have been reported in which plasma clearance of cholephilic dyes such as sulfobromophthalein (BSP) and indocyanine green (ICG) was markedly impaired, indicating a role of impaired hepatic bilirubin uptake ([@B18]; [@B10]). Genetic analyses suggest that such cases of unconjugated hyperbilirubinemia could be linked to polymorphisms in *SLCO1B1* and *SCLO1B3* ([@B21]; [@B29]; [@B9]). In the present research, four polymorphisms of *SLCO1B* identified by previous GWAS were detected ([@B14]; [@B21]; [@B15]; [@B6]). A novel founding is that variant c.521T \> C in *SLCO1B1* is closely related to bilirubin levels and significantly increases the risk of unconjugated hyperbilirubinemia (OR = 2.54, 95% CI: 1.27--5.11, *P* = 0.009). Besides, the variant c.521T \> C showed an additive effect on *UGT1A1* gene variants, particularly the variant c.211G \> A. These results indicated that the change of amino acid (valine to alanine, encoded by nucleotides 520--522) at codon 174 of *SLCO1B1* may reduce the function in unconjugated bilirubin transportation. However, the function of the variants should be validated in cell and animal model experiments. Interestingly, simultaneous homozygous mutations in *SLCO1B1* and *SLCO1B3*, resulting in disruption of hepatic reuptake of bilirubin, may account for the predominantly conjugated hyperbilirubinemia of Rotor syndrome ([@B26]). These findings suggested that the function of solute carrier organic anion transporter is more complex than transporting unconjugated bilirubin, and thus mutations in these coding genes result in different hyperbilirubinemia propensities.

Besides, previous researches have shown that genes expressed outside the liver also affect bilirubin homeostasis, including glucose-6-phosphate dehydrogenase (G6PD), heme oxygenase (HMOX), biliverdin reductase A (BLVRA), nucleoporin 153 (NUP153) and *UGT1A6* ([@B11]; [@B12]; [@B7]; [@B19]; [@B3]). However, our study mainly discussed the effects of intrahepatic genetic variations on non-hemolytic unconjugated hyperbilirubinemia. More studies are encouraged to further explore the effect of genetic variation of extrahepatic expressed genes on Chinese adult unconjugated hyperbilirubinemia.

This study has some limitation. First, the level of bilirubin in GS is fluctuating, especially in particular conditions such as prolonged fasting, fever, and strenuous exercise ([@B27]). Although we standardized blood collection and adjusted clinical factors as covariables for all association tests, there are still uncontrollable factors affecting bilirubin levels, such as mood and season. Second, the study is a descriptive study. Based on previous GWAS, our study investigated the *UGT1A1* and *SLCO1B* genetic variation of Chinese adults with hyperbilirubinemia and emphatically explored the combined effects of multiple variants. Consistent with the GWAS, our study confirmed the role of the single genetic variation. Moreover, we found that the variants of *UGT1A1* and *SLCO1B1* have combined effects on the level of bilirubin. The function of the variants should be validated in cell and animal model experiments.

In conclusion, this study demonstrates the impact of genetic factors on non- hemolytic unconjugated hyperbilirubinemia in Chinese population. Variations c.-3275T \> G, (TA)~6~\>(TA)~7~, c.211G \> A, and c.1091C \> T within *UGT1A1* as well as c.521T \> C within *SLCO1B1* are independent risk factors of mild unconjugated hyperbilirubinemia. Our results also reveal that there is a combined effect on unconjugated hyperbilirubinemia for c.-3275T \> G as well as (TA)~6~\>(TA)~7~ or c.211G \> A in *UGT1A1*. Further, co-expression of c.211G \> A of *UGT1A1* and c.521T \> C of *SLCO1B1* has a cumulative effect on unconjugated hyperbilirubinemia.
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